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A R T I C L E  I N F O A B S T R A C T
The intensive study of extracellular vesicles was start-
ed about a decade ago revealing alterations of their 
amount and content to several cellular stimuli, highly 
depending on the releasing cell type. Exosomes, a 
type of extracellular vesicles, are released by every 
cell type and are present in most body fluids, what 
makes them attractive targets of biomarker research. 
Several studies have indicated that their content – 
including proteins and coding, as well as non-coding 
nucleic acids – could represent the disease state and 
serves as specific disease biomarkers. Out of these 
molecules, a special interest was gained by long non-
coding RNAs (lncRNAs). Just as exosomes, lncRNAs 
are specific to their cell of origin and often specific to 
diseases, also found extracellularly, mainly contained 
in extracellular vesicles. Thus, recent efforts in bio-
marker research has turned to circulating exosomal 
lncRNAs, which might lead to the development of 
highly specific disease markers.
Here we summarize the current knowledge on dis-
ease-associated exosomal long non-coding RNAs. The 
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intensive studies in this area have revealed nu-
merous potential targets for biomarkers, and 
highlighted the potential of their combination 
with other exosomal markers to represent a high-
ly sensitive and specific diagnostic tool. However, 
we believe that additional functional data on 
both exosomes and lncRNAs are necessary for 
understanding their deregulation in diseases and 
developing their use as diagnostic approaches.

INTRODUCTION
The detection of soluble biomarkers from bio-
logical fluids — referred to as liquid biopsy — is 
a method that is more and more frequently ap-
plied for the early diagnosis of several diseases. It 
is believed that altered levels or the appearance 
of several circulating molecules potentially are in-
dications of disease and can be detected at early 
stages for which other — often invasive — diag-
nostic tools are ineffective. Since extracellular 
vesicles are present in body fluids and their con-
tent depends on the cell of origin, circulating ex-
tracellular vesicles could potentially serve as early 
diagnostic markers for malignant diseases (1).
Extracellular vesicles are omnipresent in human 
tissues and many types of biological fluids, in-
cluding blood, breast milk, urine, sperm, amni-
otic fluid, saliva, bronchoalveolar lavage, cere-
brospinal fluid, synovial fluid, pleura effusions 
and ascites (2). Initially, extracellular vesicles 
were considered a mechanism by which cells rid 
themselves of cytoplasm and membrane pro-
teins (3); however, not long after their discov-
ery, they were found to be truly functional and 
actively released from cells for a variety of rea-
sons. Extracellular vesicles are generally clas-
sified by their size, morphology and biochem-
ical composition as well as their biogenesis as 
apoptotic bodies, microvesicles and extracellu-
lar vesicles (2). Apoptotic bodies are the largest 
— with diameters of up to 5000 nm — and are 
released during apoptosis by direct budding of 
the membrane. These vesicles contain nuclear 
content, cell organelles, DNA, ribosomal RNA 
and messenger RNA (mRNA). Microvesicles or 
microparticles are in the mid-range of extra-
cellular vesicles with diameters of 100–1000 
nm and are formed by direct shedding of the 
plasma membrane through outward invagina-
tions. Microvesicles contain plasma membrane 
and cytosolic proteins as well as nucleic acids. 
Exosomes are small membrane nanovesicles 
released from various cells (B and T cells, den-
dritic cells, mast cells, mesenchymal stem cells, 
epithelial cells, astrocytes, endothelial cells and 
cancer cells) into the extracellular environment. 
Exosomes are the smallest extracellular vesicles, 
with diameters of 30–150 nm, and have a lipid 
bilayer containing various proteins, coding and 
non-coding RNAs and bioactive lipids, depend-
ing on their cell of origin. Exosomes are formed 
by inward budding of endosomal membranes 
that produce multivesicular bodies in which 
intraluminal vesicles develop. Intraluminal 
vesicles are subsequently secreted into the ex-
tracellular space as exosomes when multive-
sicular bodies fuse with plasma membrane (2). 
Exosomes have a plethora of biological func-
tions. In addition to mediating cell-to-cell com-
munication, signal transduction and transport of 
genetic material, exosomes play important roles 
in immune modulation and are involved in the 
pathogenesis of various human diseases, such 
as cancer and autoimmune inflammatory dis-
eases (4-6). 
During infection, exosomes carry pathogen-de-
rived proteins, nucleic acids, lipids and carbo-
hydrates and, thus, serve as antigen presenters, 
activating innate immune receptors to induce 
host defense (2). Exosomes shuttle both cod-
ing and non-coding RNAs, which maintain their 
function when transferred to recipient cells. 
This epigenetic signaling has an important role 
in cell-to-cell communication (7).
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Long non-coding RNAs (lncRNAs) are longer than 
200 nucleotide and lack protein-coding poten-
tial. These transcripts are involved in many cel-
lular processes, including the regulation of chro-
matin modification, gene transcription, mRNA 
translation and protein function. The expression 
of lncRNAs is generally tissue- or cell-type spe-
cific and malignant cells have been shown to 
have a specific lncRNA signature (8). Since these 
molecules have a role in the pathogenesis of 
many diseases, they might be used as biomark-
ers for detection of disease at early stages (6,9); 
however, the biological functions of circulating 
lncRNAs and the mechanisms regulating the levels 
of circulating lncRNAs still need to be evaluated. 
Numerous studies have confirmed that lncRNAs 
play crucial roles in various multifactorial human 
diseases, such as cancer and neurological dis-
eases, and that they also have an impact in the 
differentiation and activation of immune cells. 
These results together suggest that lncRNAs 
contribute to the pathogenesis of human in-
flammatory diseases, such as rheumatoid arthri-
tis (RA), systemic lupus erythematosus (SLE) and 
psoriasis (10).
LncRNAs have been found to be enriched in exo-
somes compared to the cell of origin (11, 12). Of 
the circulating extracelluar vesicles, exosomes 
are the richest reservoirs for almost all lncRNAs 
(13). When using lncRNAs as biomarkers, the 
circulating exosome fraction is more useful 
than whole body fluid, as exosomal lncRNAs are 
protected against RNases, they are enriched in 
the exosome fraction compared to the whole-
body fluid and their exosomal expression levels 
is dependent on the cells of origin (14). Several 
hypotheses have been proposed for the mecha-
nism by which molecules are loaded into exo-
somes. Most probably, structural motifs in the 
lncRNAs interact with the proteins responsible 
for RNA localization and exosomal loading. As 
certain RNAs are enriched in exosomes, it is 
likely that these RNAs are actively loaded into 
extracellular vesicles (2,12).
Most studies that investigate exosomes as bio-
markers have focused on cancerous diseases 
(15), and the study of exosomal lncRNAs as bio-
markers is more advanced for cancer than any 
other disease. Numerous studies indicate that 
the expression pattern of circulating lncRNAs 
probably carries information about the size of the 
tumor or malignancy or other important char-
acteristic of the disease, and, therefore, the 
presence of circulating and exosomal lncRNAs 
may reflect disease progression in particular 
cases. The use of circulating lncRNAs as bio-
markers is also emerging for chronic inflamma-
tory diseases, as many lncRNAs associated 
with these diseases are found in circulating 
exosomes. In this review, we summarize our 
knowledge about exosomal lncRNAs and their 
potential use as biomarkers for several human 
diseases, including chronic inflammatory and 
cancerous diseases.
EXOSOMAL lncRNAs  
IN CHRONIC INFLAMMATORY DISEASES 
Rheumatoid arthritis
RA is a common chronic inflammatory autoim-
mune disease that is characterized by the infil-
tration of lymphocytes and macrophages into 
the synovial fluid, hyperplasia of the synovial 
membrane, degradation of cartilage and bone 
erosion (6,9). LncRNAs seem to be implicated in 
the development of the disease, as altered ex-
pression is associated with the severity and ac-
tivity of the disease (for an extensive review see 
reference (16)). The first lncRNA that was asso-
ciated with RA was the 2.3 kb H19 RNA, which 
exhibited significantly higher expression in the 
synovial tissue of RA patients compared to the 
tissue of healthy individuals (16,17). Since this 
discovery, numerous high-throughput analyses 
were completed to describe the lncRNA profile 
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of RA from cells as well as from serum. Xu et 
al. investigated the expression of lncRNAs in 
serum samples from RA patients and healthy 
donors and identified 5 lncRNAs that were ex-
pressed at significantly higher levels in RA sam-
ples than controls: RNA143598, RNA143596, 
HIX0032090, IGHCgamma1 and XLOC_002730 
(18). Comparing the lncRNA expression in se-
rum exosomes, Song et al. found significantly 
higher expression of HOTAIR, LUST, anti-NOS2A, 
MEG9, SHNG4, TUG1 and NEAT1 and significant-
ly lower expression of mascRNA, PR antisense 
transcripts, PRINS, and HOXA3 expression in RA 
patients than in healthy individuals (19). These 
molecules are likely to serve as biomarkers for 
RA, and combined analysis of these molecules 
may be a robust method to determine disease 
prognosis. However, to date there is a lack of 
information about the sensitivity and specificity 
of these molecules in RA, therefore, until fur-
ther studies elucidate these characteristics, the 
diagnostic application of exosomal lncRNAs is 
greatly limited.
Systemic lupus erythematosus
SLE is a chronic autoimmune disease, char-
acterized by the production of multiple auto-
antibodies against nuclear auto-antigens and 
double-stranded DNA. Abnormal interaction 
between the innate and adaptive immune sys-
tem and activation of the complement system 
leads to tissue or organ damage (10,16,20). 
Lupus nephritis (LN) is one of the most seri-
ous manifestations of SLE, and 10–30% of LN 
patients progress to end-stage renal disease. 
Renal biopsy is still the “gold standard” to pre-
dict renal outcome, and a non-invasive method 
to assess glomerular damage would be major 
improvement. Recent results suggest that exo-
some-derived markers, especially from urine 
samples, might be appropriate for such an as-
say (9,21,22). Circulating exosomes in the plas-
ma of SLE patients are derived from platelets, 
endothelial cells and leukocytes and have clini-
cal and serological correlations (22). Circulating 
exosomes are also involved in the pathogenesis 
of SLE, since serum exosomes isolated from SLE 
patients were able to induce cytokine produc-
tion in peripheral blood mononuclear cells of 
healthy donors (23).
LncRNAs are strongly associated with suscep-
tibility to SLE. The gene for the GAS5 lncRNA 
is located in the SLE-susceptibility locus of 
chromosome 1q25 and is closely linked to SLE 
susceptibility (10). The GAS5 lncRNA is also 
implicated in RA pathogenesis (24), and GAS5 
levels are also downregulated in the serum of 
SLE patients (25). Moreover, serum GAS5 lev-
el could be a highly specific but not sensitive 
biomarker for SLE, and in combination with 
linc0597 lncRNA could be used as a highly sen-
sitive (83.44%) and specific (93.75%) biomark-
er (25). Expression of another lncRNA, NEAT1, 
is increased in the peripheral blood cells of 
SLE patients, as it is in RA patients (19), and is 
positively correlated with disease activity (26). 
NEAT1 often colocalizes with MALAT1, which 
is also an abnormally upregulated lncRNA in 
both RA and SLE. MALAT-1 is a key factor in the 
pathogenesis of SLE, as it regulates the expres-
sion of IL-21 and SIRT1 in monocytes from SLE 
patients (16,27). These studies on lncRNAs in 
SLE focused on either circulating lncRNAs (25) 
or cellular lncRNA expression. The fact that the 
circulating and cellular lncRNAs in SLE are also 
present in the serum exosomes of RA patients 
(19) suggests that these lncRNAs might also be 
present in serum exosomes of SLE patients. 
Future studies on exosomal lncRNAs in SLE 
could provide the necessary information to in-
clude circulating exosomal lncRNAs as disease 
specific markers in SLE.
Psoriasis
Psoriasis is a chronic inflammatory skin disease, 
characterized by the abnormal proliferation and 
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differentiation of basal keratinocytes and their 
deregulated interplay with professional immune 
cells (28). Many non-coding RNAs, including 
microRNAs (miRNAs) (29) and lncRNAs (30), 
have been found to be deregulated in this dis-
ease and implicated in disease pathogenesis. 
One of the first lncRNAs to be associated with 
psoriasis was described by our research group 
in 2005: psoriasis associated non-protein cod-
ing RNA induced by stress (PRINS). The PRINS 
lncRNA is upregulated in non-lesional skin 
samples of psoriatic patients (31) and func-
tions as a regulator of cellular apoptotic func-
tions by interacting with nucleophosmin (32) 
and miR-491-5p (33), and effecting G1P3 gene 
expression (34). PRINS also regulates inflam-
matory cytokine expression through interac-
tions with their mRNA (35).
Another regulatory lncRNA expressed in the epi-
dermis, TINCR, is localized to the cytoplasm of 
differentiated human keratinocytes and is able 
to stabilize mRNAs linked to differentiation (36), 
many of which are implicated in psoriasis patho-
genesis (30).
Approximately 10–30% of psoriatic patients 
are also affected by psoriatic arthritis (PsA), 
which causes skin symptoms as well as joint 
erosion and new bone formation. The analysis 
of lncRNAs in blood samples from PsA patients 
indicate that lncRNAs are involved in disease 
pathogenesis (37) and that these molecules 
could be used as new biomarkers and possibly 
therapeutic targets for PsA.
Although lncRNA expression in psoriatic skin 
and immune cells was described by numerous 
research groups, circulating lncRNA levels and 
exosomal lncRNAs have not received much at-
tention to date. Importantly, it has been sug-
gested that circulating exosomes could serve as 
a tool for prognosis and for monitoring therapy 
efficiency (5).
EXOSOMAL lncRNAs  
AS BIOMARKERS IN CANCER
Early diagnosis of malignant neoplasms is impor-
tant for successful treatment and survival of pa-
tients. Cancers have a high mortality rate due to 
the lack of suitable, specific and early detection 
of diagnostic tumor biomarkers. Tumor cells re-
lease exosomes, which facilitate communication 
within the local environment and primary tu-
mor cells, supporting tumor-cell growth, tumor-
associated angiogenesis and tissue inflamma-
tion in both autocrine and paracrine manners. 
Numerous studies show that cancer-derived 
exosomes activate signal-transduction pathways 
involved in cancer cell proliferation and survival 
(38,39). Exosomes regulate immune modulation, 
including immunosuppression that supports the 
growth of the tumor (4). Moreover, as exosomes 
are known to alter cellular functions, they have 
been intensively studied for their potential in 
metastasis formation, especially through the 
mechanism of epithelial-to-mesenchymal tran-
sition (40).
The peripheral blood of cancer patients con-
tains significantly more exosomes than blood 
samples from healthy individuals (41), as tu-
morous cells release higher amounts of exo-
somes. Circulating exosomes support the dis-
semination of the tumor, are involved in the 
initial events of metastasis, and carry a unique 
molecular fingerprint from their cell of ori-
gin. The high number of circulating exosomes 
and their molecular content makes them ideal 
candidates for tumor biomarkers and for pre-
dicting the metastatic potential of a tumor in 
liquid biopsies (38,42,43). However, these bio-
markers have not been integrated into clinical 
routines, as their isolation is expensive and 
time consuming (44).
Downregulation of tumor-suppressive miRNAs 
and upregulation of oncogenic miRNAs have 
been described for various human cancers. 
eJIFCC2019Vol30No2pp224-236
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Cancer-associated miRNAs regulate tumori-
genesis, survival, angiogenesis, migration and 
invasion of tumors (45); moreover, clinical stud-
ies have correlated dysregulated expression of 
particular miRNAs with tumor responsiveness 
to chemotherapies (46). 
Similarly to microRNAs, lncRNAs have been 
shown to play a fundamental role in cancer cell 
growth, proliferation, cell death, invasion and 
formation of metastasis (47); however, the ma-
jority of these genes have not yet been charac-
terized functionally. Currently, many attempts 
focus on the use of lncRNAs as prognostic mark-
ers for cancer patients, as tumor cells can be 
characterized by their distinct lncRNA profile 
(48). These lncRNAs can be packaged within 
exosomes and, as such, offer great potential for 
use as markers for specific tumors (Table 1), es-
pecially as exosomal release rate is increased in 
cancer cells compared to healthy cells (41).
The use of the exosomal lncRNAs as cancer bio-
markers is also supported by the high sensitiv-
ity (70% to 94%) (49–60) and specificity (72% 
to 94%) (49–60) of these markers. Moreover, 
the combination of either the lncRNA markers 
(58–60) or lncRNAs with miRNAs (61) or already 
used protein diagnostic markers (56,60) can 
increase both the sensitivity and specificity of 
these markers. 
This possibility was tested in prostate cancer, 
where the level of prostate specific antigen 
(PSA) is used for screening for prostate cancer 
with high specificity (~93%) but low sensitivity 
(~20–25%) at a cutoff value of 4 ng/ml (62), how-
ever it can be also modestly elevated in benign 
prostatic hyperplasia. Wang et al. suggest, that 
exosomal lncRNA expression could help differ-
entiation between prostate cancer and benign 
prostatic hyperplasia in cases, where PSA levels 
(4–10 ng/ml) alone have little diagnostic value 
(60).
EXOSOMAL lncRNAs  
IN OTHER HUMAN DISEASES
Bacterial and viral interaction with host cells
Extracellular vesicles are produced by both 
Gram-negative and Gram-positive bacteria (73) 
and have several functions, including molecular 
transport, mediation of stress response, biofilm 
formation and influence on hosts cells (2). Both 
normal human flora and pathogenic bacteria 
communicate with the host cells through extra-
cellular vesicles, and infected host cells respond 
by releasing exosomes to alert surrounding 
cells (74). The extracellular vesicles released by 
infected cells contain both pathogen- and host-
derived factors and play key roles in pathogen-
host interactions, including pathogen uptake 
and replication and regulation of the host im-
mune response (75). Viruses also modify the 
number and content of exosomes released by 
infected cells, which often contain virus-associ-
ated miRNAs, as in the case of Epstein-Barr and 
human immunodeficiency viruses, or parts of 
the viral genome (2).
Monoclonal gammopathies
Multiple myeloma is a heterogeneous disease 
with focal lesions in the bone marrow, and 
analysis of a biopsy specimen obtained from 
a single site in the bone marrow is not suf-
ficient for the prediction of disease outcome. 
However, circulating molecules (DNA, miRNAs 
and lncRNAs) in peripheral blood could serve as 
potential diagnostic, prognostic and predictive 
markers. PRINS, for which exosomal expression 
correlates with characteristic chromosomal ab-
errations in the disease, is one such candidate 
molecule (76).
Neurodegenerative diseases
LncRNAs are expressed in the central nervous 
system, which allows the possibility that they 
play roles in normal neurological development 
eJIFCC2019Vol30No2pp224-236
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and growth and, possibly, in tumorigenesis. 
Circulating and cerebrospinal-fluid-derived exo-
somes could be used to detect biomarkers for 
neurodegenerative diseases and for tumors of 
the central nervous system; however the lncRNA 
content of such exosomes has not yet been thor-
oughly investigated (77).
Osteoarthritis
By analyzing the lncRNA profile of exosomes de-
rived from plasma and synovial fluid, Zhao and 
Xu found that, whereas plasma-derived exo-
somal lncRNAs had no diagnostic value in the 
disease, PCGEM-1 was significantly upregulated 
in the synovial fluid of late-stage osteoarthri-
tis patients. 
They hypothesize that PCGEM-1 expression 
can be used to distinguish early osteoarthritis 
from the late-stage disease (78).
Chronic kidney disease
In urine-derived exosomes of patients suffering 
from chronic kidney disease 30 differentially ex-
pressed non-coding RNAs were identified as suit-
able biomarkers for early diagnosis, of which the 
most powerful disease marker is miRNA-181a, 
while lncRNAs were found to be less than 1% 
of all deregulated RNA molecules in the disease 
(79).
DISCUSSION
Liquid biopsies represent a non-invasive and 
painless method for monitoring health and 
disease states of individuals. Protein and RNA 
content of extracellular vesicles, which are pres-
ent in all body fluids, is receiving increasing lev-
els of attention for their potential as biomark-
ers. Although it seems that expression levels of 
many lncRNAs within exosomes are sufficient 
to serve as disease markers that can potentially 
be used in diagnosis or prognostic tools for hu-
man diseases, most research studying lncRNAs 
in body fluids has not determined whether the 
transcripts are freely circulating in the body fluid 
or are contained in exosomes. Moreover, most 
reports about exosomal lncRNAs show that their 
expression is deregulated in several diseases 
(Table 1), indicating that these molecules might 
not be sufficiently disease specific to be used as 
biomarkers (19,24–26).
To overcome this issue, some studies used a 
combined analysis of exosomal lncRNAs, miRNAs 
and proteins as biomarkers increasing the sen-
sitivity and specificity of the diagnostic test 
(56,58–61). Studies using such combined analy-
sis are also helpful for building interaction net-
works and databases of exosome-derived mole-
cules and support the functional study of these 
molecules necessary to understand their role in 
Exosomal lncRNA Cancer type Reported findings
CRNDE-h Colorectal cancer High levels correlate with poor prognosis (49)
ENSG00000258332.1 Hepatocellular 
carcinoma
Higher levels in serum exosomes compared to liver 
cirrhosis and chronic hepatitis B (50)
H19 Bladder cancer High levels in serum exosomes associated with poor 
disease prognosis (51)
Table 1 Exosomal lncRNAs as potential biomarkers in cancer
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HOTAIR
Bladder cancer High levels in urine-derived exosomes (63)
Cervical cancer High levels (64)
Glioblastoma 




High levels in exosomes (61)
HOTTIP Gastric cancer
Expression in exosomes is an independent prognostic 
factor (54)
HOX-AS-2 Bladder cancer High levels in urine-derived exosomes (63)
LINC00161 Hepatocellular 
carcinoma
High levels in serum-derived exosomes (55)
LINC00635 Hepatocellular 
carcinoma
Higher levels in serum exosomes than observed for 
liver cirrhosis and chronic hepatitis B (50)





Independent predictor of mortality and disease 





High levels in serum and serum exosomes (67)
lncRNA-p21 Prostate cancer
Different levels in benign prostate hyperplasia and 
prostate cancer (56)
lncRNASNHG14 Breast cancer High levels in patients resistant to trastuzumab (57)
lncUEGC1/2 Gastric cancer Highly sensitive and stable biomarker (68)
MALAT1
Bladder cancer
High levels in urine-derived exosomes (63) associated 
with poor prognosis (58) 
Cervical cancer High levels (64)
Epithelial ovarian 
cancer
Correlated with an advanced and metastatic 
phenotype and independent predictive factor for 
overall survival (69)
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disease pathogenesis and promote their use as 
biomarkers.
The intensive study of both lncRNAs and exo-
somes only started a decade ago, thus there 
are plenty of open questions. Most studies on 
both fields are still descriptive, comparing ex-
pression levels of lncRNAs or number and con-
tents of exosomes in diseased tissues, cells or 
liquid biopsies to healthy samples. But there is 
still a lack of knowledge on the function of both 
exosomes and lncRNAs in both healthy and dis-
eased states. It is also debatable whether the 
identified differences are specific to one dis-
ease or general features of related diseases. 
The expression of the same lncRNAs in several 
inflammatory diseases (19,24–26) suggest that 
their expression is rather specific to chronic in-
flammation than the disease itself. There are 
plenty of open questions in this topic: What are 
the target cells of the circulating exosomes and 
how their cargo – especially their lncRNA con-
tent – alters the function of target cells? Are the 
targeted cells specific to the disease and have a 
function in the disease course? Although there 
are some evidences that the amount of exo-
somes and their content changes with therapy 
(46,57), whether their characteristics return to 
healthy state is unknown. Nevertheless, the 
lack of consensus on exosome isolation is one 
of the biggest issue to overcome (44,80–84). 
Most methods used so far were shown to have 
high laboratory-to-laboratory and method-to-
method differences in the amount and quality 
of the isolated extracellular RNA (80), which is 
the biggest barrier before their implementation 
as routine biomarkers.
Taken these limitations into account we believe 
that the already described disease specific ex-
pression of one or more lncRNAs in exosomes 
should be the starting point to their functional 
MEG-3 Cervical cancer Low levels (64)
PCAT-1 Bladder cancer
Expression in urine-derived exosomes associated 
with poor disease prognosis (58); serum exosomal 
expression used as biomarker (59)
SAP30L-AS1 Prostate cancer
Used in combination with SChLAP1 to differentiate 
between benign prostatic hyperplasia and prostate 
cancer (60)
SChLAP1 Prostate cancer
Used in combination with SAP30L-AS1 to differentiate 
between benign prostatic hyperplasia and prostate 
cancer (60)
SNHG16 Bladder cancer High level in serum exosomes is a diagnostic marker (59)
SPINT1-AS1 Colorectal cancer High level associated with poor prognosis (71)
SPRY4-IT1 Bladder cancer
Presence in urine-derived exosomes associated with 
poor disease prognosis (58)
UBC1 Bladder cancer High level in serum exosomes is a diagnostic marker (59)
ZFAS1 Gastric cancer High serum-exosomal level (72)
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study, to provide the necessary information for 
future implications in detecting, monitoring and 
treating disease.
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